Pembrolizumab-associated chronic rhinosinusitis: A new endotype and management considerations.

Authors :: Standiford TC
Patel NN
Singh A
Gochman G
Jamie Wu T
Daud AI
Goldberg AN
Source :: International forum of allergy & rhinology [Int Forum Allergy Rhinol] 2023 Dec; Vol. 13 (12), pp. 2248-2251. Date of Electronic Publication: 2023 Jul 05.
Publication Year :: 2023
Abstract: Key Points: Patients treated with pembrolizumab experience an increase in paranasal sinus inflammation Use of topical triamcinolone in carboxymethylcellulose is a treatment option for such patients.<br /> (© 2023 ARS-AAOA, LLC.)

Subjects :: Humans
Chronic Disease
Rhinitis drug therapy
Sinusitis drug therapy
Paranasal Sinuses

Full Text Access

Tools